ArticleImmunoHorizons2026
Weakened macrophage antibacterial capacity in myelodysplastic syndrome.
Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Patients with myelodysplastic syndrome (MDS) are immunocompromised and are therefore susceptible to fatal infection. While neutropenia and neutrophil dysfunction account for much of this immunodeficiency, other immune cells likely also contribute. In contrast to the extensive study of neutrophils in MDS, there has been very little investigation of macrophage host defense function in MDS. In the current study, we find that macrophage differentiation and macrophage phagocytosis of bacteria are greatly weakened in patients with MDS, regardless of patient genotype. Moreover, we find that killing of those bacteria that are ingested is diminished in MDS patients with high-risk disease. Using a mouse model that expresses the MDS-associated U2AF1-S34F mutation, we find that this mutation is sufficient to induce macrophage functional defects. We conclude that macrophage host defense defects likely contribute to the immunodeficiency present in MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.